CA2134898A1 - Compositions et methodes de vaccination contre les coronavirus - Google Patents

Compositions et methodes de vaccination contre les coronavirus

Info

Publication number
CA2134898A1
CA2134898A1 CA002134898A CA2134898A CA2134898A1 CA 2134898 A1 CA2134898 A1 CA 2134898A1 CA 002134898 A CA002134898 A CA 002134898A CA 2134898 A CA2134898 A CA 2134898A CA 2134898 A1 CA2134898 A1 CA 2134898A1
Authority
CA
Canada
Prior art keywords
thr
val
leu
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002134898A
Other languages
English (en)
Inventor
Timothy J. Miller
Sharon Klepfer
Albert Paul Reed
Elaine V. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2134898A1 publication Critical patent/CA2134898A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002134898A 1992-05-08 1993-05-07 Compositions et methodes de vaccination contre les coronavirus Abandoned CA2134898A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88217192A 1992-05-08 1992-05-08
US07/882,171 1992-05-08
PCT/US1993/004384 WO1993023422A1 (fr) 1992-05-08 1993-05-07 Compositions et procedes de vaccination contre les coronavirus

Publications (1)

Publication Number Publication Date
CA2134898A1 true CA2134898A1 (fr) 1993-11-25

Family

ID=25380027

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002134898A Abandoned CA2134898A1 (fr) 1992-05-08 1993-05-07 Compositions et methodes de vaccination contre les coronavirus
CA002135201A Abandoned CA2135201A1 (fr) 1992-05-08 1993-05-07 Vaccin universel contre le coronavirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002135201A Abandoned CA2135201A1 (fr) 1992-05-08 1993-05-07 Vaccin universel contre le coronavirus

Country Status (5)

Country Link
EP (2) EP0640097A4 (fr)
JP (2) JPH08501931A (fr)
AU (2) AU678970B2 (fr)
CA (2) CA2134898A1 (fr)
WO (2) WO1993023421A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023423A1 (fr) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Gene s du coronavirus canin et ses applications
US6034298A (en) * 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
WO1993023421A1 (fr) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Vaccin universel contre le coronavirus
AU721367B2 (en) * 1993-02-26 2000-06-29 Wyeth Holdings Corporation Canine coronavirus vaccine from feline enteric coronavirus
EP0612532A3 (fr) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Vaccin contre le coronavirus canin à partir de coronavirus entérique félin
GB2282601B (en) * 1993-09-16 1998-04-15 Solvay Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
WO1997010347A1 (fr) * 1995-09-15 1997-03-20 Howard John A Cassettes d'expression et procedes d'administration de vaccins veterinaires
WO1998027433A1 (fr) * 1996-12-18 1998-06-25 Engene Biotechnologies, Inc Diagnostic specifique des anticorps contre le virus de la peritonite infectieuse feline
WO1999025838A1 (fr) * 1997-11-14 1999-05-27 University Of Georgia Research Foundation, Inc. Compositions et procedes destines a prevenir l'enterite de la dinde
WO2001009290A2 (fr) * 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Serotype du virus de bronchite infectieuse aviaire
FR2828405B1 (fr) * 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
TW200510450A (en) * 2003-07-21 2005-03-16 Nat Inst Health Soluble fragments of the SARS-CoV spike glycoprotein
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
ITMI20111182A1 (it) * 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
WO2015143335A1 (fr) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Méthodes et compositions pour protéines spike de coronavirus chimère
CN113248576A (zh) * 2020-02-12 2021-08-13 北京科兴中维生物技术有限公司 一种针对冠状病毒的核酸疫苗及其制备方法
WO2022020815A1 (fr) * 2020-07-24 2022-01-27 Soligenix, Inc. Compositions d'anticorps/d'adjuvants et méthodes de génération de réponse immunitaire contre les coronavirus
CN113072626B (zh) * 2021-04-25 2023-05-05 龙岩学院 一种猫冠状病毒s重组蛋白及其制备方法
CN113238048B (zh) * 2021-05-11 2024-03-15 抗码(苏州)生物科技有限公司 一种诊断标志物及其在区分新冠病毒感染和新冠病毒灭活疫苗接种中的应用
CN113861278B (zh) * 2021-06-18 2022-08-05 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN114478716B (zh) * 2021-12-28 2024-05-28 梅州市人民医院(梅州市医学科学院) 一种多肽组合及其在新型冠状病毒抗体检测中的应用
CN114773487B (zh) * 2022-05-31 2024-07-02 湖南大学 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63123385A (ja) * 1986-09-05 1988-05-27 デュファル・インテルナチオナル・レセールフ・ベー・ヴェー 新規抗原的活性蛋白質およびぺプチド、並びにネコ科感染性腹膜炎ウイルスワクチン
CA2005291C (fr) * 1988-12-30 1999-01-26 Beverly Dale Instruments de diagnostic du virus de la peritonite infectieuse des felins
WO1991002752A1 (fr) * 1989-08-22 1991-03-07 Veterinary Infectious Disease Organization Polypeptides de coronavirus bovins et vaccins contre ce virus
WO1993023423A1 (fr) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Gene s du coronavirus canin et ses applications
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
WO1993023421A1 (fr) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Vaccin universel contre le coronavirus

Also Published As

Publication number Publication date
AU678970B2 (en) 1997-06-19
AU4241093A (en) 1993-12-13
EP0640097A1 (fr) 1995-03-01
JPH08501931A (ja) 1996-03-05
EP0640097A4 (fr) 1997-01-15
WO1993023421A1 (fr) 1993-11-25
EP0640096A4 (fr) 1997-01-15
CA2135201A1 (fr) 1993-11-25
AU678971B2 (en) 1997-06-19
EP0640096A1 (fr) 1995-03-01
AU4240493A (en) 1993-12-13
JPH07508176A (ja) 1995-09-14
WO1993023422A1 (fr) 1993-11-25

Similar Documents

Publication Publication Date Title
CA2134898A1 (fr) Compositions et methodes de vaccination contre les coronavirus
JP2004313196A (ja) コロナウイルスに対するワクチン接種用組成物および方法
CN1329513C (zh) 抗猪生殖和呼吸疾病的多核苷酸疫苗制剂
US5866553A (en) Polynucleotide vaccine for papillomavirus
KR20230049084A (ko) Sars-cov-2 및 인플루엔자 조합 백신
JP2008143900A (ja) ウマの予防用ポリヌクレオチドワクチン製剤
KR20050087885A (ko) 개 질병, 특히 호흡기 및 소화성 질병 치료용폴리뉴클레오티드 백신 제제
JP2010104367A (ja) １型ウシヘルペスウイルスの欠失突然変異体、それに基づくワクチンおよび１型ウシヘルペスウイルスを検出するためのキット
EP3541419B1 (fr) Composition immunogène pour l'infection par le coronavirus mers
HUT55243A (en) Process for producing recombinant subunite vaccine against pseudolyssa
WO2022003119A1 (fr) Vaccin contre un coronavirus à réaction croisée
US6642359B2 (en) Recombinant feline coronavirus S proteins
Sakamoto et al. Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells
RU2178807C2 (ru) ВЫДЕЛЕННАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК, ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ГОМОГЕННОГО БЕЛКА gp350, ГОМОГЕННЫЙ БЕЛОК gp350, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ЕВV-СВЯЗАННОГО ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ
CA2133339A1 (fr) Glycoproteines du virus morbilleux sauvage : vaccin et methode de depistage
EP0651806B1 (fr) Vaccins contre le virus de l'immunodeficience anti-feline (vif)
JP3262787B2 (ja) 豚コレラウイルスワクチン
US20040063093A1 (en) Recombinant feline coronavirus S proteins
JP2024502837A (ja) 高病原性コロナウイルスに対する細胞傷害性ｔ細胞免疫療法
US8465748B2 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
US6602504B2 (en) Canine coronavirus S gene and uses therefor
EP0606452A1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
WO1995009249A1 (fr) Vaccination per os des mammiferes
NZ278430A (en) Epitopes capable of producing an immune response against equine arteritis virus (togaviridae) and their use
US7238672B1 (en) Chimeric lyssavirus nucleic acids and polypeptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued